Anesthetic Gas Emissions Show Global Regional Disparities
An analysis of greenhouse gas emissions from volatile anesthetic agents across 41 countries showed that Western nations have achieved significant reductions, but Asian countries continue to increase their use of the agents. South Korea and Japan reported the highest global per capita emissions.
METHODOLOGY:
Researchers conducted a multicounty analysis to estimate greenhouse gas emissions from volatile anesthetics using sales data obtained from IQVIA MIDAS and national medicines agencies.
They calculated kilograms of carbon dioxide (CO 2 ) equivalents per capita as an indicator of greenhouse gas emissions focusing on sales of desflurane, isoflurane, and sevoflurane in 41 countries, representing approximately 35% of the global population.
) equivalents per capita as an indicator of greenhouse gas emissions focusing on sales of desflurane, isoflurane, and sevoflurane in 41 countries, representing approximately 35% of the global population. The analysis compared emissions among 27 nations in the European Union with those among other Western countries like Australia, Canada, New Zealand, the UK, and the US.
Emissions among Asian countries such as China, Hong Kong, Japan, Malaysia, South Korea, Singapore, Taiwan, and Thailand were also analyzed.
Time trends and percentage changes in greenhouse gas emissions related to the procurement of volatile anesthetics from 2018 to 2023 were presented for all the groups.
TAKEAWAY:
Canada, New Zealand, and the UK showed a 65%-95% reduction in CO 2 equivalent emissions, achieving levels below 0.5 kg of CO 2 equivalents per inhabitant by 2023. Australia and the United States, despite reductions, still had higher levels of emissions.
equivalent emissions, achieving levels below 0.5 kg of CO equivalents per inhabitant by 2023. Australia and the United States, despite reductions, still had higher levels of emissions. Asian countries saw substantial increases in emissions related to volatile anesthetics, with South Korea and Japan having approximately 2.5 kg of CO 2 equivalents per inhabitant in 2023 and China experiencing a 130% rise in emissions from 2018 to 2023.
equivalents per inhabitant in 2023 and China experiencing a 130% rise in emissions from 2018 to 2023. Emissions also increased from 2018 to 2023 in some countries, including Malta, Serbia, the Czech Republic, and the Russian Federation.
Trends in emissions varied across Europe; Northern countries like Finland, Norway, and the UK showed a reduction in emissions from 1-2 kg to less than 0.5 kg of CO 2 equivalents per inhabitant, whereas Denmark and Estonia maintained low levels of emissions. Italy, Portugal, and Spain saw minimal reductions.
IN PRACTICE:
'The experience of nations that were receptive to awareness campaigns and phased out desflurane use show that reducing emissions below 0.5 kg of CO 2 e [equivalents] per inhabitant is attainable. This success should serve as a model for all the other countries, prompting them to implement educational initiatives for anaesthetists and adopt specific policies to mitigate emissions from inhalational anaesthetics,' the researchers reported.
SOURCE:
The study was led by Marta Caviglia, of the Centre for Research and Training in Disaster Medicine, Humanitarian Aid and Global Health, at the Università del Piemonte Orientale in Novara, Italy. It was published online on August 6, 2025, in Anaesthesia.
LIMITATIONS:
The study considered only greenhouse gas emissions from atmospheric release of volatile anesthetic agents, not accounting for emissions during production, packaging, transport, storage, and disposal phases. While data were available for 41 countries, there was clear overrepresentation of high-income nations, with incomplete or unavailable data from South America, Africa, and some Asian countries, including India. The analysis did not account for nitrous oxide emissions.
DISCLOSURES:
No external funding or competing interests were declared by the authors.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Aethlon Medical Inc (AEMD) Q1 2026 Earnings Call Highlights: Strategic Focus on Australian ...
Release Date: August 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aethlon Medical Inc (NASDAQ:AEMD) has made significant progress in its Australian oncology trial, with the first cohort of patients completing treatment without any device deficiencies or serious adverse events. The company has received formal approval from India's CDSCO to initiate an oncology trial, although they have decided to focus resources on the Australian trial for strategic reasons. Aethlon Medical Inc (NASDAQ:AEMD) has significantly reduced operating expenses by approximately 32%, primarily through payroll savings and reduced legal and consulting fees. The company is actively exploring the use of its hemo purifier for broader applications, including long COVID, and has presented promising pre-clinical data at a symposium. Aethlon Medical Inc (NASDAQ:AEMD) benefits from a 43% cash tax rebate in Australia, which helps offset research costs and makes conducting trials there financially advantageous. Negative Points The decision to not proceed with the Indian trial may delay potential strategic partnerships or regulatory approvals, as the company focuses solely on the Australian trial. Despite cost reductions, Aethlon Medical Inc (NASDAQ:AEMD) will still need to raise additional funds to continue its clinical research, as it does not yet have approved products for sale. The company faces challenges in accelerating patient enrollment in its Australian trial, although efforts are being made to address this through additional sites and recruitment strategies. The efficacy of the hemo purifier in actual clinical settings remains to be proven, as pre-clinical results may not directly translate to patient outcomes. Aethlon Medical Inc (NASDAQ:AEMD) is still in the early stages of its clinical trials, and it may take time to gather sufficient data to inform dosing and treatment effects. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with AEMD. Q: Can you confirm if the primary endpoint of the Australian study is safety, and if the first cohort has shown no adverse events related to the hemo purifier treatment? A: Yes, the primary endpoint is safety. We have successfully passed the first cohort with no adverse events, and an independent data safety monitoring board has recommended moving forward to the second cohort. (Dr. Steven La Rosa, Chief Medical Officer) Q: The pre-clinical data showed a 98.5% removal of extracellular vesicles in a simulated treatment. Should we expect similar results in the clinical study with actual patients? A: Laboratory results often differ from clinical outcomes. The true test will be the reduction observed in actual patients, and we hope to have data from the first cohort soon. (Dr. Steven La Rosa, Chief Medical Officer) Q: With the decision not to proceed with the Indian trial, what does this mean for your cash needs and strategic focus? A: We will need to continue raising funds, ideally with strategic partners. The decision to halt the Indian trial was more about avoiding delays in approval processes rather than cost savings. (Jim Frakes, CEO and CFO) Q: Are there any advantages to conducting clinical research in Australia compared to India, especially regarding costs and incentives? A: Australia offers a significant tax rebate of about 43%, which is not available in India. This rebate can make conducting research in Australia more cost-effective despite lower hospital costs in India. (Jim Frakes, CEO and CFO) Q: What efforts are being made to accelerate patient enrollment in the Australian trial? A: We are actively working on several initiatives, including pre-screening logs, recruiting additional sites, and using clinical trial liaisons and social media campaigns to speed up enrollment. (Dr. Steven La Rosa, Chief Medical Officer) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Medscape
2 hours ago
- Medscape
More Pregnancies With Weight Loss Before IVF
Women with obesity who lost weight prior to in vitro fertilization (IVF) had increased pregnancy rates, especially unassisted conceptions, a systematic review and meta-analysis has found. The studies reviewed were small and heterogeneous, making it difficult to determine which weight loss interventions had the most efficacy, according to the authors. Still, they concluded that weight loss in this cohort might 'negate the need for treatment, and does not seem to increase the risk for pregnancy loss, although evidence on the effect on live births was unclear.' The results were published online August 12 in the Annals of Internal Medicine. Obesity is associated with ovulatory dysfunction, reduced ovarian responsiveness to agents that induce ovulation, altered oocyte and endometrial function, and lower birth rates after IVF, according to an opinion published by the Practice Committee of the American Society for Reproductive Medicine in 2021. Previously, it was unknown whether weight loss before IVF improves reproductive outcomes, so Moscho Michalopoulou, MSc, DPhil, a behavioral scientist at Oxford University in the United Kingdom, and a team of researchers reviewed 12 randomized controlled studies (RCTs) of 1921 women with obesity who were offered a weight loss intervention before planned IVF. The studies included in the analysis were of women in upper-middle or high-income countries who had a median body mass index of 33.6 kg/m2. They were typically in their early 30s, and their weight loss prior to conception tended to be modest across the studies included. Nearly a quarter of women from nine studies had polycystic ovary syndrome. Weight loss in this PCOS population was associated with fewer unassisted conceptions. There were numerous weight loss interventions across the RCTs, and their median duration of an active weight loss phase was 12 weeks (range 5 - 24 weeks). Controls across the studies in the analysis received usual care, yet in six studies they received no or minimal intervention. In the remaining six studies, usual care was a less intense weight loss intervention than in the study arm. Participants across all intervention groups lost 4 kg more than controls, the researchers found. The difference in weight change between groups was larger when interventions were compared with no or minimal intervention rather than to an active control. The average follow-up for reproductive outcomes was 9.3 months (range 1.3 - 18 months) for intervention groups vs 11.2 months (range 4.3 - 24 months) for controls. Ten studies reported unassisted pregnancy rates (1466 participants). Eight studies favored intervention; however, most studies had few unassisted pregnancies, resulting in wide confidence intervals. Overall, the investigators found that weight loss interventions before IVF were associated with greater unassisted pregnancy rates (relative risk, 1.47; 95% CI, 1.26 - 1.73). The effect size was greater in the RCTs with controls involving no or minimal intervention vs an active weight loss comparator, although the small number of studies and events limited formal comparison. No consistent pattern was observed when studies were sorted by the difference in weight change between groups, age, or baseline BMI, but the study authors found a tendency for fewer unassisted pregnancies with an increasing proportion of women with PCOS in the sample. 'There was inconclusive evidence on the effect of weight loss interventions on treatment-induced pregnancies. Overall, evidence on the association between weight loss interventions before IVF and live births was uncertain, although there was moderate certainty of no association with pregnancy loss,' the investigators write. The authors noted that a weakness in their study was a lack of follow-up on pregnancy outcomes. 'Unfortunately, fewer studies reported live birth outcomes, not all studies followed up on unassisted conceptions to determine live birth, and evidence on live births was further limited by heterogeneity in study design and clinical characteristics of recruited populations,' the authors write. Another deficit in the study, according to the authors, was that the studies reviewed had 'marked variability in eligibility and in participant characteristics that affect IVF success and could have influenced the effect of weight loss interventions on outcomes.' According to an accompanying editorial written by Alan S. Penzias, MD,'[The authors] highlight for future investigators the need for studies that include outcomes, including pregnancy loss and live birth, for both medically assisted and unassisted pregnancies.' Penzias directs the Fellowship Program in Reproductive Endocrinology and Infertility at the Boston IVF/Beth Israel Deaconess Medical Center, and is an associate professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School, Boston, Massachusetts. The women in the studies Michalopoulou and her colleagues analyzed tended to be in their early 30s, which Penzias focused on in his editorial. 'A woman's age is the strongest predictor of successfully becoming pregnant,' he writes. 'The association of increasing age with reduced fecundity is so strong that some advocate consideration of IVF as a first-line treatment strategy in women older than 38 to 40 years. It is critical to balance the time it takes to achieve weight loss and the benefit of weight loss on medically unassisted conception.' Penzias suggested that in addition to a woman's age, her preferred family size, which cannot be determined by weight loss, must also be factored in when deciding whether to use IVF. 'It is important to understand that once an oocyte is retrieved via IVF, any embryo created from its fertilization will always carry the success rate associated with the woman's age at the time of retrieval,' Penzias writes. For Cate Varney, DO, an associate professor in the Department of Family Medicine at University of Virginia School of Medicine in Charlottesville, the age of the woman seeking to become pregnant does matter, but that 'it is well-established that obesity plays a significant role in infertility. There is a gap in the data between the association and modifiable risk,' she told Medscape Medical News. 'The timing and amount of clinically meaningful weight loss will be important to identify so we can clarify the trade-offs between delaying IVF for weight loss vs age-related fertility decline,' said Varney, who is also the obesity medicine director at UVA Health. The study was supported by the National Institute for Health and Care Research Applied Research Collaboration Oxford and Thames Valley. The study authors and editorialist Penzias reported no relevant financial relationships. Varney is an advisor and in the speaker's bureau for Eli Lilly.
CNET
5 hours ago
- CNET
Ultrahuman Calls Ring Air the World's Most Accurate Ovulation-Tracking Smart Ring After New Acquisition
Ultrahuman has taken an algorithm designed for intravaginal fertility monitors and transformed it into a non-invasive, temperature-sensing feature that can track your cycle right from your finger. The wearable health tech company announced today that it acquired viO HealthTech, which created the OvuSense algorithm. Validated in 13 peer-reviewed clinical publications and backed by 15 years of clinical research, the algorithm draws on data from over 260,000 cycles collected with medical-grade sensors. It was previously used in class II intravaginal medical fertility monitors. Now, Ultrahuman has adapted that technology for wellness tracking to create its Cycle and Ovulation Pro PowerPlug for the Ring Air. In a press release, Ultrahuman said Cycle and Ovulation Pro delivers over 90% accuracy in confirming ovulation -- a level the company says makes the Air the "world's most accurate cycle-tracking smart ring." This data comes from equivalence testing that compared OvuSense and Ring AIR with a multi-hormone ovulation prediction method that tracks rises in luteinizing hormone and progesterone. Though other cycle trackers may report different ovulation confirmation rates -- for example, the Oura Ring claims 96.4% -- that data isn't directly comparable to OvuSense and Ring Air's testing due to differences in validation protocols, datasets and definitions of detection. Ultrahuman Most platforms that track menstrual cycles rely on a 28-day cycle, but Cycle and Ovulation Pro takes into consideration that 87% of people who menstruate have varying cycles due to conditions such as polycystic ovary syndrome, endometriosis, non-bleeding, thyroid disorders or irregular bleeding. "This collaboration benefits from 15 years of clinically proven women's health expertise and applies it to the world's lightest smart ring," said Mohit Kumar, Ultrahuman CEO, in the press release. "For the first time, best-in-class hardware, software and algorithms with a clinical background come together in one wellness device. Our mission is to give women cutting-edge tools to optimize their health, combining clinical technology with comfort and style to deliver the most accurate women's health tool available." Cycle and Ovulation Pro complements Ultrahuman Ring Air's existing free Cycle and Ovulation PowerPlug, which provides basic conception and cycle tracking. Using physiological patterns and temperature biomarkers passively captured by the smart ring, the Pro version can support fertility planning, offer a space for mood, symptom and behavior logging and use temperature data to suggest hidden patterns in a cycle. Known as Cycle Flags, these patterns may include early, late or absent ovulation, a short luteal phase and trends potentially linked to conditions such as PCOS or miscarriage risk. Ultrahuman While the OvuSense algorithm is FDA-cleared for intravaginal use, the adapted, non-invasive version for the Ultrahuman Ring Air was created for general wellness and isn't FDA-cleared. In other words, the Ring Air isn't a substitute for contraception or for professional medical diagnosis and treatment. For those, you should consult your health care provider. How much does Ultrahuman's Cycle and Ovulation Pro cost? Now available in the US, UK, EU, Australia and Canada, Cycle and Ovulation Pro is a premium PowerPlug in the Ultrahuman app that costs $3.99 per month or $39.99 per year. The current Cycle and Ovulation PowerPlug remains free.
